Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 1 PART1, 2006, Pages 122-128

  Ikeda, Masafumi ^a,b   Fujiyama, Shigetoshi ^c   Tanaka, Motohiko ^c   Sata, Michio ^d   Ide, Tatsuya ^d   Yatsuhashi, Hiroshi ^e   Watanabe, Hiroshi ^f  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NTT West Kyushu Hospital   (Japan)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^f FUKUOKA UNIVERSITY   (Japan)

Author keywords

Follow up; Hepatitis C virus; Hepatocellular carcinoma; Interferon; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; BETA INTERFERON; INDOCYANINE GREEN; INTERFERON; SERUM ALBUMIN; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFORMATION PROCESSING; JAPAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; TREATMENT WITHDRAWAL; TUMOR VOLUME;

EID: 33645227447     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.04083.x     Document Type: Article

References (29)

1. Colombo M Kuo G Choo QL et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma Lancet 1989 2 1006 8
2. Kew MC Houghton M Choo QL Kuo G Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma Lancet 1990 335 873 4
3. Kiyosawa K Sodeyama T Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus Hepatology 1990 12 671 5
4. Takano S Yokosuka O Imazeki F Tagawa M Omata M Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients Hepatology 1995 21 650 5
5. Causse X Godinot H Chevallier M et al. Comparison of 1 or 3 MU of interferon α-2b and placebo in patients with chronic non-A, non-B hepatitis Gastroenterology 1991 101 497 502
6. Davis GL Balart LA Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group NEnglJMed 1989 321 1501 6
7. Nishiguchi S Kuroki T Nakatani S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 1995 346 1051 5
8. Yoshida H Shiratori Y Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy AnnInternMed 1999 131 174 81
9. Ikeda K Saitoh S Arase Y et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis Hepatology 1999 29 1124 30
10. Okanoue T Itoh Y Minami M et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group JHepatol 1999 30 653 9
11. Shiratori Y Imazeki F Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy AnnInternMed 2000 132 517 24
12. Kasahara A Hayashi N Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group Hepatology 1998 27 1394 402
13. Imai Y Kawata S Tamura S et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group AnnInternMed 1998 129 94 9
14. Yoshida H Arakawa Y Sata M et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients Gastroenterology 2002 123 483 91
15. Yoshida H Tateishi R Arakawa Y et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C Gut 2004 53 425 30
16. Hirashima N Mizokami M Orito E et al. Development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha JGastroenterolHepatol 1996 11 955 8
17. Tong MJ Lai LP Murakami-Mori K Development of hepatocellular carcinoma after clearance of hepatitis C virus with interferon therapy WestJMed 1997 167 103 5
18. Miyano S Togashi H Shinzawa H et al. Occurrence of hepatocellular carcinoma 4.5 years after successful treatment with virus clearance for chronic hepatitis C JGastroenterolHepatol 1999 14 928 30
19. Yamada M Ichikawa M Matsubara A Ishiguro Y Yamada M Yokoi S Development of small hepatocellular carcinoma 80 months after clearance of hepatitis C virus with interferon therapy EurJGastroenterolHepatol 2000 12 1029 32
20. Makiyama A Itoh Y Kasahara A et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy Cancer 2004 101 1616 22
21. Toyoda H Kumada T Tokuda A et al. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C. Yon-Ken HCV-HCC Follow-up Study Group JViral Hepatol 2000 7 414 19
22. Toyoda H Kumada T Hayashi K et al. Characteristics and prognosis of hepatocellular carcinoma detected in sustained responders to interferon therapy for chronic hepatitis C. Yon-Ken HCV-HCC Follow-up Study Group Cancer DetectPrev 2003 27 498 502
23. Ikeda K Kobayashi M Saitoh S et al. Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients Oncology 2003 65 204 10
24. Toyoda H Kumada T Honda T et al. Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C JGastroenterolHepatol 2001 16 1131 7
25. Kashiwagi K Furusyo N Kubo N et al. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development JInfectChemother 2003 9 333 40
26. Suzuki K Ohkoshi S Yano M et al. Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis Liver Int 2003 23 143 7
27. Yoneyama K Yamaguchi M Kiuchi Y Morizane T Shibata M Mitamura K Analysis of background factors influencing long-term prognosis of patients with chronic hepatitis C treated with interferon Intervirology 2002 45 11 19
28. Desmet VJ Gerber M Hoofnagle JH Manns M Scheuer PJ Classification of chronic hepatitis: diagnosis, grading and staging Hepatology 1994 19 1513 20
29. Fong TL Shindo M Feinstone SM Hoofnagle JH Di Bisceglie AM Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C JClinInvest 1991 88 1058 60